Genprex

Monthly Archives: November 2020

Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Company expects to recruit approximately 10 sites across the United States

Read More

Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1

Presentation to Highlight the Promise of Novel Gene Therapies to Transform Cancer and Diabetes Treatments

Read More

Genprex to Participate in Panel at Life Sciences Summit on November 17

Thomas Gallagher, Senior VP of Intellectual Property and Licensing, to provide insight into IP best practices to early-stage companies

Read More

Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD

Inventor of the Company’s licensed diabetes gene therapy technology to provide leadership, strategy for diabetes program

Read More

Genprex cancer gene therapy paired with AZ, Merck lung cancer drugs

An experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Co’s Keytruda – both leading their respective drug classes in the treatment of non-small cell lung cancer (NSCLC).

Read More

Genprex to Combine Reqorsa With Checkpoint, EGFR Inhibitors in Lung Cancer Studies

Genprex announced that quaratusugene ozeplasmid (Reqorsa) will be studied in two new trials, in which non-small cell lung cancer patients with specific molecular markers will receive its investigational drug combined with osimertinib (AstraZeneca’s Tagrisso) or pembrolizumab (Merck’s Keytruda).

Read More